Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 8/20 | 0.47 |
| ▸ | KCNK9 | Q9NPC2 | 8/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298812 | 0.88 | CNR2 (0.44) | KCNK3KCNK9CDK2CDK4LMNA | |
| SCHEMBL1298642 | 0.78 | KCNK3 (0.40) | KCNK3KCNK9CDK2CDK4LMNA | |
| SCHEMBL1298321 | 0.77 | SMN1; SMN2 (0.44) | CDK2LMNANPC1PKMRAB9A | |
| SCHEMBL1299266 | 0.72 | ALDH1A1 (0.40) | LMNANPC1RAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL1299131 | 0.69 | PTGS1 (0.45) | NPC1RAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL1298563 | 0.68 | MAPK1 (0.57) | RAB9ASMN1; SMN2RXFP1 | |
| SCHEMBL30785076 | 0.67 | MAPT (0.58) | PIN1LMNANPC1PKMRAB9A | |
| SCHEMBL5001832 | 0.67 | CDK1 (0.45) | CDK2CDK4PIN1SMN1; SMN2CHRNA7 | |
| SCHEMBL3835912 | 0.67 | CDK1 (0.47) | CDK2CDK4PIN1SMN1; SMN2CHRNA7 | |
| SCHEMBL8180872 | 0.67 | PIN1 (0.50) | KCNK3KCNK9PIN1LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2011-11-03 | — | — | US | disclosed |
| WO-2010002472-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | KCNK3 1283/4885KCNK9 2616/4885CDK2 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.